Dulanermin, the first recombinant soluble human TRAIL (aa114‐281) [38], has completed clinical trials from Phase 1 to Phase 3 in patients of non‐small cell lung cancer [39, 40, 41], B‐cell lymphomas [42], colorectal cancer [43], or non‐Hodgkin's lymphoma [44], either as monotherapy or in combination with other anticancer therapies. This evidence concerns the gene TNFSF10 and colorectal cancer.